var data={"title":"Factor VIII, recombinant human with Fc fusion: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Factor VIII, recombinant human with Fc fusion: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/796749?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=factor-viii-recombinant-human-with-fc-fusion-patient-drug-information\" class=\"drug drug_patient\">see &quot;Factor VIII, recombinant human with Fc fusion: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46566162\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Eloctate</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46850182\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Eloctate</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46566165\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antihemophilic Agent</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46566195\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hemophilia A:</b> IV: Individualize dosage based on coagulation studies performed prior to treatment and at regular intervals during treatment. In general, administration of factor VIII 1 unit/kg will increase circulating factor VIII levels by ~2 units/dL.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">\n      <b>Control and prevention of bleeding episodes or perioperative management:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">\n      <i>Manufacturer's labeling:</i> Refer to manufacturer's labeling for specific recommendations.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">\n      <i>Alternate recommendations (WFH [Srivastava 2013]):</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">\n      <i>Dosage based on desired factor VIII increase (%):</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">To calculate dosage needed based on desired factor VIII increase (%): </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">[Body weight (kg) x desired factor VIII increase (%)] divided by 2 (%/units/kg)  = units factor VIII required </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">For example:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">50 kg x 30 (% increase) divided by 2  = 750 units factor VIII </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <i>Dosage based on expected factor VIII increase (%):</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">It is also possible to calculate the <b>expected</b> % factor VIII increase: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">[# units administered x 2 (%/units/kg)] divided by body weight (kg) = expected % factor VIII increase </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">For example: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">[1,400 units x 2] divided by 70 kg = 40% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>World Federation of Hemophilia (WFH) treatment recommendations when no significant resource constraint exists (WFH [Srivastava 2013]): </b></p>\n    <table border=\"1\" rules=\"all\" frame=\"border\">\n      <caption style=\"text-align:center;\">2013 World Federation of Hemophilia Treatment Recommendations (When No Significant Resource Constraint Exists)</caption>\n      <col align=\"left\"></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <thead valign=\"middle\">\n        <tr>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Site of Hemorrhage/Clinical Situation </p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Desired Factor VIII Level to Maintain </p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Duration</p></th></tr></thead>\n      <tfoot valign=\"middle\">\n        <tr>\n          <td colspan=\"3\" valign=\"middle\" align=\"left\">\n            <p style=\"text-indent:0em;text-align:left;\">\n              <b>Note:</b> Factor VIII level may either be expressed as units/dL or as %. Dosing frequency most commonly corresponds to the half-life of factor VIII but should be determined based on an assessment of factor VIII levels before the next dose.</p></td></tr></tfoot>\n      <tbody valign=\"middle\">\n        <tr>\n          <td align=\"left\">\n            <p style=\"text-indent:0em;\">Joint </p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">40 to 60 units/dL </p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">1 to 2 days, may be longer if response is inadequate </p></td></tr>\n        <tr>\n          <td align=\"left\">\n            <p style=\"text-indent:0em;\">Superficial muscle/no neurovascular compromise </p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">40 to 60 units/dL </p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">2 to 3 days, sometimes longer if response is inadequate </p></td></tr>\n        <tr>\n          <td rowspan=\"2\" align=\"left\">\n            <p style=\"text-indent:0em;\">Iliopsoas and deep muscle with neurovascular injury, or substantial blood loss</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <i>Initial:</i> 80 to 100 units/dL </p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <i>Initial:</i> 1 to 2 days </p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <i>Maintenance:</i> 30 to 60 units/dL </p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <i>Maintenance:</i> 3 to 5 days, sometimes longer as secondary prophylaxis during physiotherapy </p></td></tr>\n        <tr>\n          <td rowspan=\"2\" align=\"left\">\n            <p style=\"text-indent:0em;\">CNS/Head</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <i>Initial:</i> 80 to 100 units/dL </p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <i>Initial:</i> 1 to 7 days </p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <i>Maintenance:</i> 50 units/dL </p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <i>Maintenance:</i> 8 to 21 days </p></td></tr>\n        <tr>\n          <td rowspan=\"2\" align=\"left\">\n            <p style=\"text-indent:0em;\">Throat and neck </p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <i>Initial:</i> 80 to 100 units/dL </p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <i>Initial:</i> 1 to 7 days </p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <i>Maintenance:</i> 50 units/dL </p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <i>Maintenance:</i> 8 to 14 days </p></td></tr>\n        <tr>\n          <td rowspan=\"2\" align=\"left\">\n            <p style=\"text-indent:0em;\">Gastrointestinal </p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <i>Initial:</i> 80 to 100 units/dL </p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <i>Initial:</i> 7 to 14 days </p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <i>Maintenance:</i> 50 units/dL </p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <i>Maintenance:</i> Not specified </p></td></tr>\n        <tr>\n          <td align=\"left\">\n            <p style=\"text-indent:0em;\">Renal </p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">50 units/dL </p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">3 to 5 days </p></td></tr>\n        <tr>\n          <td align=\"left\">\n            <p style=\"text-indent:0em;\">Deep laceration </p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">50 units/dL </p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">5 to 7 days </p></td></tr>\n        <tr>\n          <td rowspan=\"4\" align=\"left\">\n            <p style=\"text-indent:0em;\">Surgery (major) </p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <i>Preop:</i> 80 to 100 units/dL </p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\"></p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <i>Postop:</i> 60 to 80 units/dL </p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <i>Postop:</i> 1 to 3 days </p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <i>Postop:</i> 40 to 60 units/dL </p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <i>Postop:</i> 4 to 6 days </p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <i>Postop:</i> 30 to 50 units/dL </p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <i>Postop:</i> 7 to 14 days </p></td></tr>\n        <tr>\n          <td rowspan=\"2\" align=\"left\">\n            <p style=\"text-indent:0em;\">Surgery (minor) </p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <i>Preop:</i> 50 to 80 units/dL </p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\"></p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <i>Postop:</i> 30 to 80 units/dL </p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <i>Postop:</i> 1 to 5 days depending on procedure type </p></td></tr></tbody></table>\n    \n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">\n      <b>Routine prophylaxis to prevent or reduce the frequency of bleeding episodes:</b>  IV: 50 units/kg every 4 days; at 3- to 5-day intervals, may adjust dose within the range of 25 to 65 units/kg based on patient response. Maintain trough levels between 1% and 3% above baseline, or higher, as clinically indicated.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46566196\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hemophilia A:</b> Children and Adolescents: IV: Individualize dosage based on coagulation studies performed prior to treatment and at regular intervals during treatment. In general, administration of factor VIII 1 unit/kg will increase circulating factor VIII levels by ~2 units/dL. Children &lt;6 years may require higher doses and/or more frequent administration.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Control and prevention of bleeding episodes or perioperative management:</b> <i>Refer to adult dosing.</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Routine prophylaxis to prevent bleeding episodes:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children &lt;6 years: 50 units/kg twice weekly; at 3- to 5-day intervals, may adjust dose within the range of 25 to 65 units/kg based on patient response. More frequent or higher doses (up to 80 units/kg) may be required.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children &ge;6 years and Adolescents: Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46566197\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46566199\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling; however, renal impairment has no bearing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46566200\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46566212\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Eloctate: 250 units (1 ea); 500 units (1 ea); 750 units (1 ea); 1000 units (1 ea); 1500 units (1 ea); 2000 units (1 ea); 3000 units (1 ea); 4000 units (1 ea); 5000 units (1 ea); 6000 units (1 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46566163\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46566214\" class=\"block dosfc drugH1Div\"><span class=\"drugH1\">Dosage Forms Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Strengths expressed with approximate values. Consult individual vial labels for exact potency within each vial.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46566202\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">IV: Infuse at a rate of &le;10 mL/minute (maximum: 10 mL/minute)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">According to the World Federation of Hemophilia (WFH), infuse by slow IV injection at a rate not to exceed 3 mL/minute (adults) or 100 <b>units</b>/minute (young children) (WFH [Srivastava 2013]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46566168\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Hemophilia A: </b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Control and prevention of bleeding episodes:</b> For the prevention and control of bleeding episodes in adults and children with hemophilia A.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Perioperative management:</b> For surgical prophylaxis in adults and children with hemophilia A.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Routine prophylaxis to prevent or reduce the frequency of bleeding:</b> For routine prophylactic treatment to prevent or reduce the frequency of bleeding episodes in adults and children with hemophilia A.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Limitation of use: Not indicated for the treatment of von Willebrand disease.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46566158\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Factor VIII may be confused with Factor XIII</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Other safety concerns:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Confusion may occur due to the omitting of  &quot;Factor VIII&quot; from some product labeling. Review product contents carefully prior to dispensing any antihemophilic factor.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46566175\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Antibody development (Factor VIII inhibitor development), arthralgia, back pain, bradycardia, chest pain, cough, dizziness, dysgeusia, feeling hot, headache, hot flash, hypertension, joint swelling, lower abdominal pain, malaise, myalgia, procedural hypotension, sensation of cold, skin rash, venous pain (postinjection)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46566172\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Life-threatening hypersensitivity to antihemophilic factor or any component of the formulation.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46566173\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Antibody formation: The development of factor VIII antibodies has been reported with antihemophilic factors; monitor for signs of formation of antibodies to factor VIII; may occur at any time but more common in young children with severe hemophilia. Suspect factor VIII antibodies if the plasma factor VIII level does not increase as expected or if bleeding is not controlled after administration.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hypersensitivity reactions: Allergic hypersensitivity reactions (including anaphylaxis) may occur; discontinue if hypersensitivity symptoms occur and administer appropriate treatment. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Sucrose: May contain sucrose. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Dose requirements: The dosage requirement will vary in patients with factor VIII inhibitors; optimal treatment should be determined by clinical response.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46566182\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46566179\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=109079&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Emicizumab-kxwh: May enhance the thrombogenic effect of Factor VIII Products.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46566170\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have not been conducted. Factor VIII concentrations may increase in pregnant women with coagulation disorders. Pregnant women should have clotting factors monitored, particularly at 28 and 34 weeks gestation and prior to invasive procedures. Prophylaxis may be needed if concentrations are &lt;50 units/mL at term and treatment should continue for 3 to 5 days postpartum depending on route of delivery. Because parvovirus infection may cause hydrops fetalis or fetal death, a recombinant product is preferred if prophylaxis or treatment is needed. The neonate may also be at an increased risk of bleeding following delivery and should be tested for the coagulation disorder (Kadir 2009; Lee 2006).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46566171\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if antihemophilic factor (recombinant [Fc Fusion Protein]) is excreted in breast milk. According to the manufacturer, the decision to breast-feed during therapy should take into account the risk of exposure to the infant and the benefits of treatment to the mother.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46566204\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Heart rate and blood pressure (before and during IV administration); plasma factor VIII activity prior to and during treatment; development of factor VIII inhibitors; signs of bleeding; hemoglobin, hematocrit; hypersensitivity reactions </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46566190\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:0em;display:inline\">Classification of hemophilia; normal is defined as 1 unit/mL of factor VIII</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Severe: Factor level &lt;1% of normal</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Moderate: Factor level 1% to 5% of normal</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Mild: Factor level &gt;5% to &lt;40% of normal</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46566188\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Factor VIII replacement, necessary for clot formation and maintenance of hemostasis. It activates factor X in conjunction with activated factor IX; activated factor X converts prothrombin to thrombin, which converts fibrinogen to fibrin, and with factor XIII forms a stable clot.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46566191\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>ss</sub>: Children &lt;12 years: ~0.52 to 0.59 dL/kg; Children &ge;12 years, Adolescents, and Adults: ~0.50 to 0.6 dL/kg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">Half-life elimination: Children &lt;12 years: 12.7 to 14.9 hours; Children &ge;12 years, Adolescents, and Adults: 16.4 to 19.7 hours</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46566215\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Eloctate Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 unit (Price provided is per AHF Unit): $2.53</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 unit (Price provided is per AHF Unit): $2.53</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">750 unit (Price provided is per AHF Unit): $2.53</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1000 unit (Price provided is per AHF Unit): $2.53</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1500 unit (Price provided is per AHF Unit): $2.53</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2000 unit (Price provided is per AHF Unit): $2.53</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">3000 unit (Price provided is per AHF Unit): $2.53</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4000 unit (Price provided is per AHF Unit): $2.53</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5000 unit (Price provided is per AHF Unit): $2.53</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">6000 unit (Price provided is per AHF Unit): $2.53</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46902777\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Elocta (AT, CZ, DE, DK, EE, FR, GB, IE, LT, NO, PL, PT, RO, SI, SK);</li>\n      <li>Eloctate (AU, JP, NZ)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Eloctate (antihemophilic factor [recombinant]) [prescribing information]. Cambridge, MA: Biogen Idec; January 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Eloctate (antihemophilic factor [recombinant]) [prescribing information]. Mississauga, Ontario, Canada: Bioverativ Canada Inc; October 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kadir R, Chi C, Bolton-Maggs P. Pregnancy and rare bleeding disorders. <i>Haemophilia</i>. 2009;15(5):990-1005. doi: 10.1111/j.1365-2516.2009.01984.x.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/factor-viii-recombinant-human-with-fc-fusion-drug-information/abstract-text/19298378/pubmed\" target=\"_blank\" id=\"19298378\">19298378</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lee CA, Chi C, Pavord SR, et al. The obstetric and gynaecological management of women with inherited bleeding disorders--review with guidelines produced by a taskforce of UK Haemophilia Centre Doctors' Organization. <i>Haemophilia</i>. 2006;12(4):301-336.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/factor-viii-recombinant-human-with-fc-fusion-drug-information/abstract-text/16834731/pubmed\" target=\"_blank\" id=\"16834731\">16834731</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Srivastava A, Brewer AK, Mauser-Bunschoten EP, et al; Treatment Guidelines Working Group on Behalf of The World Federation Of Hemophilia. Guidelines for the management of hemophilia. <i>Haemophilia</i>. 2013;19(1):e1-e47.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/factor-viii-recombinant-human-with-fc-fusion-drug-information/abstract-text/22776238/pubmed\" target=\"_blank\" id=\"22776238\">22776238</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 109079 Version 26.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F46566162\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F46850182\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F46566165\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F46566195\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F46566196\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F46566197\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F46566199\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F46566200\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F46566212\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F46566163\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms Considerations\" href=\"#F46566214\" class=\"outlineLink\">Dosage Forms Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F46566202\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F46566168\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F46566158\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F46566175\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F46566172\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F46566173\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F46566182\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F46566179\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F46566170\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F46566171\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F46566204\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F46566190\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F46566188\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F46566191\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F46566215\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F46902777\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/109079|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=factor-viii-recombinant-human-with-fc-fusion-patient-drug-information\" class=\"drug drug_patient\">Factor VIII, recombinant human with Fc fusion: Patient drug information</a></li></ul></div></div>","javascript":null}